KINSIE FISHER: Open Payments
NPI 1306254131 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,642 in 89 payments from 15 companies in 2025. Trend: 2023 $1,031 · 2024 $1,188 · 2025 $1,642
Food & beverage: $1,642
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $465 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $246 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $221 |
| Madrigal Pharmaceuticals | 5 | $184 |
| Janssen Biotech, Inc. | 5 | $119 |
| GENZYME CORPORATION | 4 | $105 |
| Ferring Pharmaceuticals Inc. | 4 | $74 |
| Lilly USA, LLC | 3 | $61 |
| Ardelyx, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
Products named: XIFAXAN, ENTYVIO, RINVOQ, REZDIFFRA, DUPIXENT, TREMFYA, LINZESS, REBYOTA.
Industry payments across IN — which companies pay providers there.
